A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses

Journal of Virology

Volumn 86, Issue 6, 2012, Pages 2978-2989

  Hu, Hongxing ^a   Voss, Jarrod ^b   Zhang, Guoliang ^c   Buchy, Philippi ^d   Zuo, Teng ^e   Wang, Lulan ^a   Wang, Feng ^a   Zhou, Fan ^a   Wang, Guiqing ^a   Tsai, Cheguo ^a   Calder, Lesley ^b   Gamblin, Steve J ^b   Zhang, Linqi ^e   Deubel, Vincent ^d   Zhou, Boping ^c   Skehel, John J ^b   Zhou, Paul ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c Shenzhen Third Hospital   (China)

^d INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

^e Tsinghua University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

100F4 ANTIBODY; 3C11 ANTIBODY; 65C6 ANTIBODY; ANTIVIRUS AGENT; EPITOPE; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; SIALIDASE; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; AVIAN INFLUENZA VIRUS; BINDING AFFINITY; CELL SECRETION; CLADISTICS; CONTROLLED STUDY; DROSOPHILA; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ELECTRON MICROSCOPY; EPITOPE MAPPING; FEMALE; HUMAN; HUMAN CELL; INFECTION PREVENTION; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MEMORY CELL; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PSEUDOTYPING; SCREENING TEST; SENSITIVITY ANALYSIS; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CONSERVED SEQUENCE; EPITOPE MAPPING; EPITOPES; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS;

AVES; INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE;

EID: 84863229743     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06665-11     Document Type: Article

References (54)

1. Beigel JH, et al. 2005. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med. 353:1374 -1385.
2. Buchy P, et al. 2007. Influenza A/H5N1 virus infection in humans in Cambodia. J. Clin. Virol. 39:164 -168.
3. Chen Y, et al. 2009. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. J. Infect. Dis. 199:49 -58.
4. Corti D, et al. 2010. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120:1663-1673.
5. Corti D, et al. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333:850-856.
6. de Jong MD, et al. 2006. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12:1203- 1207.
7. de Jong MD, et al. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353:2667-2672.
8. Ekiert DC, et al. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324:246 -251.
9. Ekiert DC, et al. 2011. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333:843- 850.
10. Gu J, et al. 2007. H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet 370:1137-1145.
11. Gutiérrez R, Naughtin M, Horm S, San S, Buchy P. 2009. A(H5N1) virus evolution in South East Asia. Viruses 1:335-361.
12. Ha Y, Stevens DJ, Skehel JJ, Wiley DC. 2002. H5 avian and H9 swine influenza virus haemagglutinin structures: possible origin of influenza subtypes. EMBO J. 21:865- 875.
13. Hanson BJ, et al. 2006. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir. Res. 7:126.
14. Johansson DX, et al. 2007. Efficient expression of recombinant human monoclonal antibodies in Drosophila S2 cells. J. Immunol. Methods 318: 37-46.
15. Kashyap AK, et al. 2008. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc. Natl. Acad. Sci. U. S. A. 105:5986 -5991.
16. Kashyap AK, et al. 2010. Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries. PLoS Pathog. 6:e1000990.
17. Kaverin NV, et al. 2007. Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J. Virol. 81:12911-12917.
18. Khurana S, et al. 2009. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med. 6:e1000049.
19. Koudstaal W, et al. 2009. Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir. J. Infect. Dis. 200:1870 -1873.
20. Le QM, et al. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108.
21. Lu J, et al. 2006. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab=)2 in mice. Respir. Res. 7:43.
22. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. 2006. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann. Intern. Med. 145:599-609.
23. Luo G, Chung J, Palese P. 1993. Alterations of the stalk of the influenza virus neuraminidase: deletions and insertions. Virus Res. 29:321.
24. Oh HL, et al. 2010. An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses. J. Virol. 84:8275- 8286.
25. Okuno Y, Matsumoto K, Isegawa Y, Ueda S. 1994. Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J. Virol. 68:517-520.
26. Palladino G, Mozdzanowska K, Washko G, Gerhard W. 1995. Virusneutralizing antibodies of immunoglobulinG(IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J. Virol. 69: 2075-2081.
27. Peiris JS, et al. 2004. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363:617- 619.
28. Puck JM, Glezen WP, Frank AL, Six HR. 1980. Protection of infants from infection with influenza A virus by transplacentally acquired antibody. J. Infect. Dis. 142:844-849.
29. Reed, LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27:493- 497.
30. Renegar KB, Small PA, Jr, Boykins LG, Wright PF. 2004. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J. Immunol. 173:1978 -1986.
31. Reuman PD, Paganini CM, Ayoub EM, Small PA, Jr. 1983. Maternalinfant transfer of influenza-specific immunity in the mouse. J. Immunol. 130:932-936.
32. Sawyer LA. 2000. Antibodies for the prevention and treatment of viral diseases. Antiviral Res. 47:57-77.
33. Simmons CP, et al. 2007. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med. 4:e178.
34. Smirnov YA, Lipatov AS, Gitelman AK, Claas EC, Osterhaus AD. 2000. Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in theHAstem region. Arch. Virol. 145:1733-1741.
35. Smith GJ, et al. 2006. Emergence and predominance of an H5N1 influenza variant in China. Proc. Natl. Acad. Sci. U. S. A. 103:16936 -16941.
36. Sui J, et al. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16:265-273.
37. Sun L, et al. 2009. Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses. PLoS One 4:e5476.
38. Sweet C, Bird RA, Jakeman K, Coates DM, Smith H. 1987. Production of passive immunity in neonatal ferrets following maternal vaccination with killed influenza A virus vaccines. Immunology 60:83- 89.
39. Sweet C, Jakeman KJ, Smith H. 1987. Role of milk-derived IgG in passive maternal protection of neonatal ferrets against influenza. J. Gen. Virol. 68:2681-2686.
40. Throsby M, et al. 2008. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3:e3942.
41. Tiller T, et al. 2008. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329:112-124.
42. Traggiai E, et al. 2004. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10:871- 875.
43. Tran TH, et al. 2004. Avian influenza A (H5N1) in 10 patients in Vietnam. N. Engl. J. Med. 350:1179 -1188.
44. Tsai C, et al. 2009. Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase. Vaccine 27: 6777-6790.
45. Whittle JR, et al. 2011. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc. Natl. Acad. Sci. U. S. A. 108:14216 -14221.
46. Wrammert J, et al. 2011. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med.
47. Wrammert J, et al. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453:667- 671.
48. Wrigley NG, et al. 1983. Electron microscopy of influenza haemagglutininmonoclonal antibody complexes. Virology 131:308-314.
49. Xu R, et al. 2010. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328:357-360.
50. Yoshida R, et al. 2009. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog. 5:e1000350.
51. Yu X, et al. 2008. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 455:532-536.
52. Zhou B, Zhong N, Guan Y. 2007. Treatment with convalescent plasma for influenza A (H5N1) infection. N. Engl. J. Med. 357:1450 -1451.
53. Zhou P, Goldstein S, Devadas K, Tewari D, Notkins AL. 1998. Cells transfected with a nonneutralizing antibody gene are resistant to HIV infection: targeting the endoplasmic reticulum and trans-Golgi network. J. Immunol. 160:1489 -1496.
54. Zuo T, et al. 2011. Comprehensive analysis of pathogen-specific antibody response in vivo based on an antigen library displayed on the surface of yeast. J. Biol. Chem. 286:33511-33519.